Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 11/20 | 0.51 |
| ▸ | STAT6 | P42226 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | BCR | P11274 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 3/20 | 0.41 |
| ▸ | VNN1 | O95497 | 1/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 2/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.39 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19010320 | 0.93 | NTRK1 (0.52) | NTRK1ABL1BCRVNN1GFER | |
| SCHEMBL17021403 | 0.92 | NTRK1 (0.49) | NTRK1STAT6JAK3IRAK4 | |
| SCHEMBL17021284 | 0.90 | GFER (0.52) | NTRK1STAT6JAK3SYKGFER | |
| SCHEMBL17021272 | 0.90 | NTRK1 (0.59) | NTRK1STAT6JAK3 | |
| SCHEMBL19010311 | 0.87 | NTRK1 (0.51) | NTRK1ABL1BCRNTRK3NTRK2 | |
| SCHEMBL17021297 | 0.85 | WNT3A (0.46) | NTRK1STAT6JAK3SYKGFER | |
| SCHEMBL19010321 | 0.85 | NTRK1 (0.59) | NTRK1STAT6JAK3 | |
| SCHEMBL17021422 | 0.84 | GRM5 (0.45) | NTRK1STAT6JAK3IRAK4 | |
| SCHEMBL17021313 | 0.84 | ADORA2B (0.43) | NTRK1STAT6JAK3IRAK4 | |
| SCHEMBL19010276 | 0.83 | GFER (0.54) | NTRK1STAT6JAK3SYKGFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9834548-B2 | Pyridazine compounds as JAK inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-9834548-B2 | Pyridazine compounds as JAK inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-20170174673-A1 | PYRIDAZINE COMPOUNDS AS JAK INHIBITORS | ALEXION PHARMACEUTICALS, INC. | 2017-06-22 | — | — | US | disclosed |
| US-20170174673-A1 | PYRIDAZINE COMPOUNDS AS JAK INHIBITORS | ALEXION PHARMACEUTICALS, INC. | 2017-06-22 | — | — | US | disclosed |
| WO-2015123453-A1 | PYRIDAZINE COMPOUNDS AS JAK INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2015-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174673-A1 | PYRIDAZINE COMPOUNDS AS JAK INHIBITORS | JAK1, JAK2, JAK3 | NTRK1 1410/4885STAT6 8/4885ABL1 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.